OxyFile #441


Title: The Seeming Anomaly of Hydrogen Peroxide
Source: Townsend Letter for Doctors & Patients
Date: June 1996

You might think one of the bad guys couldn't be useful in therapy.
The explanation is found in the extremely low concentration used -
typically, 0.04%.  Some competent researchers fear that active 
oxygen creates free radicals in the body, and so might promote 
arterial damage and cancer, acccelerate aging and do other 

But when active oxygen as ozone (O3) or hydrogen peroxide (H2O2) 
is used at the right low concentration, the highly reactive oxygen 
free radicals are beneficial rather than harmful.  Why? Negative 
and positive electrical charges attract eaach other.  The body is
negatively charged; microbes, viruses and toxins are positively

Active oxygen is negatively charged; and so if there's enough
negative oxygen to neutralize the positive invaders, all is well.
If not, then the positively charged bad guys stick to the
negatively charged body instead of being washed out.  And so
these oxygen free radicals scavenge dangerous free radicals.

Oxygen therapies are legal everywhere except the U.S. 
In Europe, the therapies are being used by 5,000 individual
physicians, although doctors in major hospitals and medical 
centers ridicule them.  Medical schools teach what pharmaceutical
companies research and what government health agencies grant
research money for; and what both of these groups study is
what is patentable and so makes money.

To "justify" their policy, in the Federal Register in 1974 the 
FDA cited research showing that atmospheric ozone irritates the
lungs of sick people, and so declared it a toxic, illegal gas
without medical application.  Of course, no one uses ozone that 
way, and the FDA ignores the many successful therapies.

However, thanks to political pressure from Senator Tom Harkin, 
Phase I trials for toxicity have been completed at University of
Naples, Italy.  HIV and hepatitis B infected subjects were treated
for three months using Medizone Corporation's patented technology.
Infected blood was exposed to an ozone/oxygen mixture diffused 
through an extacorporeal blood-carrying device, then restored to
the patient; matched control groups were treated with a placebo.

As in any double blind test, neither the subjects nor the doctors
running the test know who is getting what - until the therapy 
begins to produce better health - or, in drug tests, adverse side 
effects. Participants are being tracked for nine months.  If this 
finds the therapy safe, phase 2 tests for effectiveness will 
follow in Italy and perhaps in the U.S.